This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
However, in patients with urea cycle disorders, genetic defects result in inadequate amounts of the enzymes needed to convert nitrogen into urea. The University of California Los Angeles are currently investigating the use of genetically altered hepatocyte-like cells generated from induced pluripotent stem cells. Future Possibilities.
This month, we highlight new appointments from Lumeris, Lineage Cell Therapeutics, 1910 Genetics, and ADC Therapeutics. . ” Patrick Genestin, 1910 Genetics . “I am excited to join 1910 Genetics at such a pivotal time for the company,” Genestin said. Ben Grabski, Lumeris.
.–( BUSINESS WIRE )– EdiGene, Inc. which develops genome editing technologies to accelerate drug discovery and develop novel therapeutics for a broad range of diseases, today announced the appointment of Bo Zhang, Ph.D., as Head of BusinessDevelopment. Both will report to Dr. Dong Wei, CEO of EdiGene.
The production of commercial dose non-sterile products such as tablets, capsules, ointments, creams, and powders is rising due to their growing global demand, attributed to increasing demand for anti-ageing products, hereditary factors, genetic mutations, exposure to harmful radiation, and rising geriatric population.
While nucleic acid amplification tests - a type of viral diagnostic test for a virus or bacterium that detects genetic materials rather than antigens or antibodies - can provide a shorter turnaround time, they come with challenges, ranging from their complex nature to the intensity of labour required in their creation.
Now, he leads Whitelab Genomics as its artificial intelligence (AI) platform powers the development of genomic therapies – an emerging field in which genetic sequences are injected into cells to target and repair damaged genes. Inactive viruses often act as the viral vector, as they’re able to deliver genetic therapies efficiently.
The GBT deal comes at a time when the market for SCD therapies is undergoing significant change, with multiple new drugs reaching the market after years of stagnation and progress also being made with genetic therapies from the likes of bluebird bio, Vertex Pharma/CRISPR Therapeutics and Precision Bio/Novartis.
In other cases, rare CNS conditions may be passed on from one generation to the next without knowledge or understanding that the reason for suffering or death among previous generations was genetic in basis and therefore identifiable, and perhaps even treatable.
The funding will offer capital to extend Blueprint’s varied pipeline toward marketing as well as to continue seeking strategic and synergistic businessdevelopment prospects. This genetic-led approach will also aid in expediting the approval of new treatments. Innovation.
Dan McDonald, vice president, global businessdevelopment. Imogen Cheese, Imperial director of businessdevelopment, U.K. Wearables will be developed that notify patients and EMS services of precursors to adverse events. Gene counselors and genetic testing. Instead we are blasting forward at record pace.
It is estimated that there are currently more than 7,000 orphan diseases, many of which are considered life-threatening and most of which have a genetic basis. Despite this high number, orphan diseases are rare by definition, affecting around one in 2,000 people as defined by the European Union.
Mitochondrial dysfunctions cause more than 50 diseases, including Alzheimer’s and Parkinson’s diseases and rare genetic disorders. Paolo is a life sciences executive with over 20 years of experience in venture capital, R&D, external innovation, and businessdevelopment. Supporting efforts to address mitochondrial diseases.
Pharmaceutical companies are putting their trust in the immense potential this new generation of medicine has for treating individuals with rare genetic diseases, which currently affect an estimated 280 million patients worldwide. Cell and gene therapies are not your typical clinical supply chain.
The committee is tasked with supporting BeyondSpring’s businessdevelopment activities related to its lead asset, Plinabulin, and other pipeline assets. Mukul Agarwal, former vice president of Corporate Development, at Forty Seven, Inc., BeyondSpring – BeyondSpring Inc. Sabbagh will replace David Thompson who is retiring.
Prior to joining Calliditas Therapeutics as CMO, he held roles at GlaxoSmithKline (GSK) and Takeda, focusing on clinical and businessdevelopment in rare diseases. I’ve had a great passion for drug development in rare diseases,” says Dr. Philipson, underscoring a commitment that would shape his career’s trajectory.
Nasdaq:LOGC) (LogicBio), a company dedicated to extending the reach of genetic medicine with pioneering targeted delivery platforms, announced today the U.S. LogicBio Therapeutics is dedicated to extending the reach of genetic medicine with pioneering targeted delivery platforms. LEXINGTON, Mass., About LogicBio Therapeutics.
Most recently, Cadavid served as senior vice president and Head of Clinical Development at Fulcrum Therapeutics where he led the development of multiple small molecules for the treatment of genetically defined rare diseases. She joined VMS BioMarketing in 2008 and has served as its president and CEO since 2011.
Now poised to advance a robust therapeutics pipeline to clinical development, Nuance will use the funds for ongoing R&D of existing products and businessdevelopment of potential new assets. Through its Shielded Living Therapeutics platform, the company is developing functional cures for chronic diseases.
AlzeCure aims to pursue its own projects through preclinical research and development to an early clinical phase and is continuously working with businessdevelopment to find suitable out-licensing solutions with other pharmaceutical companies.
The main risk factors to develop Alzheimer’s are age and genetic causes.
Corporate and BusinessDevelopment Update. The Company’s 2020 financial guidance does not assume the completion of any significant businessdevelopment transactions not completed as of the date of this press release. (4). government.
Dr. Lin has made several transitions throughout her career, from being a clinician at an academic center, to academic research, to heading businessdevelopment in industry. Working on finding therapies for genetic diseases at NeuBase, Dr. Sooter says, “Everyday, we get up and that’s our goal and it really drives everyone.
The FDA has granted V181, the company’s investigational dengue vaccine in Phase 1 development, Fast Track designation.
BusinessDevelopments.
formerly known as Seattle Genetics, Inc.)
Merck and Seagen Inc.
In APAC, for example, industry commentators are predicting that the pharmaceutical sector’s historic focus on genetics and manufacturing will shift towards cutting-edge technology. Against this backdrop, new specialisations are cropping up in regional investment activity and cash raising techniques. Source: GlobalData.
Jamaels recently brought together members of the businessdevelopment team and new starters face-to-face for the first time to brainstorm how to remain competitive and price smarter. “When you have teams talking to each other and understanding each other’s requirements, then you can improve processes and raise the quality of the work.”
It’s home to the highest genetic diversity of humans on the planet and it’s filled with potential participants who are more and more urbanised and eager to be part of the clinical trials.” However, Africa currently accounts for a very low percentage of global clinical trials, with estimates putting it at approximately 2.5%. “You
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content